Celgene Corporation (CELG) Wednesday announced that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration, of the FDA, has set November 8, 2012 as the date for review of the company's New Drug Application for Pomalidomide.
The integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation, announced that it is seeking approval to market pomalidomide in combination with dexamethasone as a potential treatment for patients with relapsed and refractory multiple myeloma that has progressed following at least two prior therapies.
Pomalidomide is not approved in the U.S. for the treatment of multiple myeloma.
For comments and feedback: editorial@rttnews.com